Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all
Filter Results
Filter Results
General (513) Financials (98) Partnerships (72) Ad hoc (37) New Products (34) Acquisitions (25) New Technologies (10)
Corporate (394) Specialized Modalities (118) Integrated Biologics (98) Capsules & Health Ingredients (63) Advanced Synthesis (29)
2025 (9) 2024 (24) 2023 (25) 2022 (39) 2021 (65) 2020 (84) 2019 (101) 2018 (91) 2017 (79) 2016 (75) 2015 (57) 2014 (59)
English (606) Deutsch (98) French (4)
Reset Filters
   Loading...
Showing 1‐20 of 500
15 May 2025
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Andreas Bohrer has served as Lonza’s Group General Counsel and Company Secretary since 2015  As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal &...
09 May 2025
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Jean-Marc Huët was re-elected as Chair of the Board of Directors  Juan Andres, Eric Drapé and David Meline have been elected as Members of the Board of Directors Shareholders...
09 May 2025
Lonza gibt Ergebnisse der Generalversammlung 2025 bekannt – Alle Anträge des Verwaltungsrates wurden genehmigt
Jean-Marc Huët wurde als Präsident des Verwaltungsrates wiedergewählt Juan Andres, Eric Drapé und David Meline wurden als Mitglieder des Vewaltungsrates gewählt Die...
09 May 2025
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in Line with Expectations for Full-Year 2025
Strong CDMO1 performance in Q1 2025, in line with expectations for FY 2025 Robust commercial demand in CDMO business with high utilization in early-stage business, Bioscience...
03 Apr 2025
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Annual General Meeting will take place on 9 May 2025 at the Congress Center in Basel, Switzerland Jean-Marc Huët proposed for re-election as Chair of the Board of Directors...
01 Apr 2025
Lonza Implements its Simplified and Streamlined Operating Model
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure is now replaced with three newly...
01 Apr 2025
Lonza Completes its Share Buyback Program
Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through...
29 Jan 2025
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin
In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1) CORE EBITDA of CHF 1.9 billion at a margin of 29.0% The CDMO2  business delivered a...
29 Jan 2025
Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29.0% Kern-EBITDA-Marge
Im Jahr 2024 erzielte Lonza einen Umsatz von CHF 6.6 Milliarden (-0.2% kWk1  gegenüber dem Vorjahr) Kern-EBITDA von CHF 1.9 Milliarden ergab eine Marge von 29.0% Das...
12 Dec 2024
​​Lonza Investor Update 2024​ Outlines Strategy, New Organizational Structure and Guidance
Lonza has provided an overview of its new “One Lonza” strategy and new organizational structure
12 Nov 2024
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand 2,000m2 of...
24 Oct 2024
Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024
Outlook 2024 confirmed: Flat year-on-year sales in CER and a CORE EBITDA margin of high 20s  Strong commercial and operational performance across the CDMO business in...
22 Oct 2024
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The...
03 Oct 2024
Lonza Nominates David Meline as Independent Board Member
David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors Olivier Verscheure will not stand for re-election at the 2025 Annual...
01 Oct 2024
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche
The Vacaville site is one of the largest biologics manufacturing facilities in the world Acquisition extends Lonza’s US Biologics footprint with a significant presence on the...
24 Sep 2024
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply CASGEVY® will be manufactured at Lonza’s Geleen (NL) cell...
28 Aug 2024
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche...
25 Jul 2024
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at the Lonza Group Annual General Meeting (AGM) in May 202...
25 Jul 2024
Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin​
Lonza has reported sales of CHF 3.1 billion, growing 1.8% CER (-0.7% AER). CHF 893 million CORE EBITDA resulted in a robust margin of 29.2%, supported by favorable product mix and sustained demand for commercial CDMO services.
25 Jul 2024
​​2024 Halbjahresperformance der Lonza Gruppe in Übereinstimmung mit Gesamt-jahresprognose: Umsatzwachstum von 1.8% kWk und 29.2% Kern-EBITDA-Marge​
Lonza verzeichnete einen Umsatz von CHF 3.1 Milliarden, was einer Umsatzsteigerung von 1.8% in konstanten Wechselkursen (kWk) (-0.7% AER)2 entspricht. Das Kern-EBITDA von CHF 893 Millionen führte zu einer robusten Marge von 29.2%, unterstützt von einer an...